 |
 |
|
|
|  PubMed
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
3 June 2003 | Volume 138 Issue 11 | Pages 917-924
Clinical trials have demonstrated that angiotensin-converting enzyme (ACE) inhibitors, ß-blockers, and spironolactone improve survival in patients with heart failure. Because patients with heart failure and renal insufficiency have been underrepresented in these trials, little evidence is available to guide clinicians in the optimal management of patients with both conditions. Approximately one third to one half of patients with heart failure have renal insufficiency (estimated glomerular filtration rate [GFR] <60 mL/min per 1.73 m2), and renal insufficiency is among the strongest predictors of mortality in patients with heart failure. Evidence supports the use of ACE inhibitors to improve survival in patients with moderate renal insufficiency (GFR, 30 to 60 mL/min per 1.73 m2), but there is little evidence with which to weigh the risks and benefits in patients with more advanced renal dysfunction. ß-Blockers improve survival in patients with heart failure, and their beneficial effect is unlikely to differ according to renal function. Spironolactone improves outcomes in patients with advanced heart failure, but renal insufficiency appears to increase risk for hyperkalemia and limits the use of the drug in patients with severe renal insufficiency. Future clinical trials in heart failure should include a representative number of patients with renal insufficiency to improve the evidence base and outcomes in this vulnerable population.
Author and Article Information
From the Veterans Affairs Medical Center and University of California, San Francisco, San Francisco, California.
Grant Support: Dr. Shlipak is funded by a Research Career Development Award from the Health Services Research and Development Service of the Veterans Affairs Administration and by grant RO3 HL68099-01 from the National Institutes of Health.
Acknowledgments: The author thanks Drs. Barry Massie, Glenn Chertow, and Maria Ansari for their helpful comments on this manuscript and Ms. Michelle Odden for her technical assistance.
Potential Financial Conflicts of Interest: None disclosed.
Requests for Single Reprints: Michael G. Shlipak, MD, MPH, General Internal Medicine Section, Veterans Affairs Medical Center (111A1), 4150 Clement Street, San Francisco, CA 94121; e-mail, shlip{at}itsa.ucsf.edu. PERSPECTIVE
Pharmacotherapy for Heart Failure in Patients with Renal Insufficiency
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Facebook 
Reddit 
Technorati 
Twitter What's this?
Related articles in Annals:
This article has been cited by other articles:
|
|
 |
|
  B. K. Nallamothu, R. A. Hayward, and E. R. Bates Beyond the Randomized Clinical Trial: The Role of Effectiveness Studies in Evaluating Cardiovascular Therapies Circulation, September 16, 2008; 118(12): 1294 - 1303. [Full Text] [PDF]
|
|
|
|
 |
|
 J. W. Ely, J. A. Osheroff, S. M. Maviglia, and M. E. Rosenbaum Patient-Care Questions that Physicians Are Unable to Answer J. Am. Med. Inform. Assoc., July 1, 2007; 14(4): 407 - 414. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M Kleber, M Cybulla, K Bauchmuller, G Ihorst, B Koch, and M Engelhardt Monitoring of renal function in cancer patients: an ongoing challenge for clinical practice Ann. Onc., May 1, 2007; 18(5): 950 - 958. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. de Silva, N. P. Nikitin, K. K.A. Witte, A. S. Rigby, H. Loh, A. Nicholson, S. Bhandari, A. L. Clark, and J. G.F. Cleland Effects of applying a standardised management algorithm for moderate to severe renal dysfunction in patients with chronic stable heart failure Eur J Heart Fail, April 1, 2007; 9(4): 415 - 423. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Lainscak, J. G.F. Cleland, M. J. Lenzen, F. Follath, M. Komajda, and K. Swedberg International variations in the treatment and co-morbidity of left ventricular systolic dysfunction: Data from the EuroHeart Failure Survey Eur J Heart Fail, March 1, 2007; 9(3): 292 - 299. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. S. Blix, K. K. Viktil, T. A. Moger, and A. Reikvam Use of renal risk drugs in hospitalized patients with impaired renal function--an underestimated problem? Nephrol. Dial. Transplant., November 1, 2006; 21(11): 3164 - 3171. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. G. Coca, H. M. Krumholz, A. X. Garg, and C. R. Parikh Underrepresentation of renal disease in randomized controlled trials of cardiovascular disease. JAMA, September 20, 2006; 296(11): 1377 - 1384. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. A. McAlister, W. A. Ghali, Y. Gong, J. Fang, P. W. Armstrong, and J. V. Tu Aspirin Use and Outcomes in a Community-Based Cohort of 7352 Patients Discharged After First Hospitalization for Heart Failure Circulation, June 6, 2006; 113(22): 2572 - 2578. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. L. Smith, J. H. Lichtman, M. B. Bracken, M. G. Shlipak, C. O. Phillips, P. DiCapua, and H. M. Krumholz Renal Impairment and Outcomes in Heart Failure: Systematic Review and Meta-Analysis J. Am. Coll. Cardiol., May 16, 2006; 47(10): 1987 - 1996. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. R. Marcy and T. L. Ripley Aldosterone antagonists in the treatment of heart failure Am. J. Health Syst. Pharm., January 1, 2006; 63(1): 49 - 58. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Ezekowitz, F. A. McAlister, K. H. Humphries, C. M. Norris, M. Tonelli, W. A. Ghali, M. L. Knudtson, and APPROACH Investigators The association among renal insufficiency, pharmacotherapy, and outcomes in 6,427 patients with heart failure and coronary artery disease J. Am. Coll. Cardiol., October 19, 2004; 44(8): 1587 - 1592. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Bibbins-Domingo, F. Lin, E. Vittinghoff, E. Barrett-Connor, D. Grady, and M. G. Shlipak Renal insufficiency as an independent predictor of mortality among women with heart failure J. Am. Coll. Cardiol., October 19, 2004; 44(8): 1593 - 1600. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. S. Anavekar, J. J.V. McMurray, E. J. Velazquez, S. D. Solomon, L. Kober, J.-L. Rouleau, H. D. White, R. Nordlander, A. Maggioni, K. Dickstein, et al. Relation between Renal Dysfunction and Cardiovascular Outcomes after Myocardial Infarction N. Engl. J. Med., September 23, 2004; 351(13): 1285 - 1295. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. G. Shlipak and B. M. Massie The Clinical Challenge of Cardiorenal Syndrome Circulation, September 21, 2004; 110(12): 1514 - 1517. [Full Text] [PDF]
|
|
|
|
|
|
B. F. Palmer Managing Hyperkalemia Caused by Inhibitors of the Renin-Angiotensin-Aldosterone System N. Engl. J. Med., August 5, 2004; 351(6): 585 - 592. [Full Text] [PDF]
|
|
|
|
 |
|
 M. G. Shlipak, G. L. Smith, S. S. Rathore, B. M. Massie, and H. M. Krumholz Renal Function, Digoxin Therapy, and Heart Failure Outcomes: Evidence from the Digoxin Intervention Group Trial J. Am. Soc. Nephrol., August 1, 2004; 15(8): 2195 - 2203. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Ahmed Use of Angiotensin-Converting Enzyme Inhibitors in Heart Failure and Renal Insufficiency Ann Intern Med, June 1, 2004; 140(11): 931 - 932. [Full Text] [PDF]
|
|
|
|
|
|
A. Spital Renal Insufficiency and Heart Failure Therapy Ann Intern Med, April 6, 2004; 140(7): 584 - 584. [Full Text] [PDF]
|
|
|
|
|
|
F. A. McAlister, J. Ezekowitz, M. Tonelli, and P. W. Armstrong Renal Insufficiency and Heart Failure: Prognostic and Therapeutic Implications From a Prospective Cohort Study Circulation, March 2, 2004; 109(8): 1004 - 1009. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. A. McAlister Applying Evidence to Patient Care: From Black and White to Shades of Grey Ann Intern Med, June 3, 2003; 138(11): 938 - 939. [Full Text] [PDF]
|
|
